Allogene Therapeutics Inc — Quarterly Financial Statistics (NASDAQ:ALLO) | MetaTrader

Open full chart

Financials

Overview 성명 Statistics

Quarterly Annual

Cash from operating activities -36.7 M-52.93 M-39.03 M-29.69 M-27.6 M -149.25 M Cash from investing activities 54.93 M6.18 M43.84 M11.94 M33.61 M 95.56 M Cash from financing activities 5.74 M13.99 M5.07 M3.24 M7.86 M 30.16 M Free cash flow -36.95 M-53.03 M-39.07 M-29.93 M-27.6 M -149.63 M

뉴스

ALLO Rises on Strong MRD Clearance With Cema-Cel in ALPHA3 Study

Company News for Apr 14, 2026

Allogene Therapeutics, Inc. (ALLO) Discusses Interim Futility Analysis from Pivotal Phase II ALPHA 3 Trial in First-Line Consolidation Large B-Cell Lymphoma - Slideshow (NASDAQ:ALLO) 2026-04-14

Allogene Therapeutics, Inc. (ALLO) Discusses Interim Futility Analysis from Pivotal Phase II ALPHA 3 Trial in First-Line Consolidation Large B-Cell Lymphoma Transcript

Allogene: Early ALPHA3 Data Suggests Potential Paradigm Shift For Cema-Cel In LBCL

Caribou Biosciences: Antlers Up For The Allogenic CAR-T Bet Trading At Cash Value

시티즌, Allogene 파이프라인 진전에 주식 등급 재확인

Citizens reiterates Allogene stock rating on pipeline progress

Allogene Therapeutics, Inc. (ALLO) Q4 2025 Earnings Call Transcript

Allogene Therapeutics, 4분기 EPS 예상치 상회

Earnings call transcript: Allogene Therapeutics beats Q4 2025 EPS forecast

Take the Zacks Approach to Beat the Markets: Starbucks, Amgen, Allogene in Focus